Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

University of Calgary

$110,000.00

Pathophysiology and course of irritable bowel syndrome (IBS)-like symptoms in inactive inflammatory bowel disease (IBD): A longitudinal prospective study

FY 2011-12

Summary
Crohn's disease (CD) and ulcerative colitis (UC), known as inflammatory bowel diseases (IBD), are chronic inflammatory conditions of the digestive tract. Canada has one of the highest incidence and prevalence rates of IBD in the world. Based on our group's validated administrative definition, it is estimated that approximately 19,000 IBD patients reside in the province of Alberta. Quality of life of IBD patients is negatively affected and is driven primarily by the clinical symptoms. Currently the goal of medical therapy is to control the symptoms by reducing the intestinal inflammation. However, many patients continue to suffer from debilitating irritable bowel syndrome-like (IBS) symptoms such as abdominal pain, bloating and diarrhea despite healing of their bowel lining. As per our meta-analysis, 57% and 37% of treated UC and CD patients fall into this category, respectively. These patients have poor quality of life and undergo unnecessary and potentially harmful investigations. Despite the clinical importance, little is known about the course, pathogenesis and associated digestive disorders in these patients (IBD-IBS). In our proposed study, we will closely follow 80 adult IBD patients for 3-6 months after they are started on medical therapy in Calgary Health zone. We will identify IBD patients who develop IBS-like symptoms and compare the presence of multiple inflammatory markers in the blood, stool and colon biopsy samples with IBS patients and healthy controls. This will be the first study in IBD-IBS patients to prospectively examine the proposed inflammatory markers in response to treatment and associate these findings with abdominal pain. It will characterize the natural history of IBD-IBS, associated digestive conditions and risk factors which will enhance physician awareness in management of this disease. Moreover, knowledge about the risk factors and pathogenesis of IBD-IBS will lead to identification of potential prophylactic or therapeutic targets.
Program
CIHR Fellowship
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
248116
Name
Rezaie Ali
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Pathophysiology and course of irritable bowel syndrome (IBS)-like symptoms in inactive inflammatory bowel disease (IBD): A longitudinal prospective study
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$110,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Barostat Balloon; Crohn'S Disease; Immunohistochemistry; Inflammatory Bowel Disease; Irritable Bowel Syndrome; Manometry; Natural History Of Disease; Polymerase Chain Reaction; Transient Receptor Potential Vanilloid Type 1; Ulcerative Colitis
Abstract
Crohn's disease (CD) and ulcerative colitis (UC), known as inflammatory bowel diseases (IBD), are chronic inflammatory conditions of the digestive tract. Canada has one of the highest incidence and prevalence rates of IBD in the world. Based on our group's validated administrative definition, it is estimated that approximately 19,000 IBD patients reside in the province of Alberta. Quality of life of IBD patients is negatively affected and is driven primarily by the clinical symptoms. Currently the goal of medical therapy is to control the symptoms by reducing the intestinal inflammation. However, many patients continue to suffer from debilitating irritable bowel syndrome-like (IBS) symptoms such as abdominal pain, bloating and diarrhea despite healing of their bowel lining. As per our meta-analysis, 57% and 37% of treated UC and CD patients fall into this category, respectively. These patients have poor quality of life and undergo unnecessary and potentially harmful investigations. Despite the clinical importance, little is known about the course, pathogenesis and associated digestive disorders in these patients (IBD-IBS). In our proposed study, we will closely follow 80 adult IBD patients for 3-6 months after they are started on medical therapy in Calgary Health zone. We will identify IBD patients who develop IBS-like symptoms and compare the presence of multiple inflammatory markers in the blood, stool and colon biopsy samples with IBS patients and healthy controls. This will be the first study in IBD-IBS patients to prospectively examine the proposed inflammatory markers in response to treatment and associate these findings with abdominal pain. It will characterize the natural history of IBD-IBS, associated digestive conditions and risk factors which will enhance physician awareness in management of this disease. Moreover, knowledge about the risk factors and pathogenesis of IBD-IBS will lead to identification of potential prophylactic or therapeutic targets.
Competitiondate
201110
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Rezaie, Ali
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $110,000~ $0~